Biotechnology company Creative Medical Technology Holdings Inc (OTCQB:CELZ) reported on Friday the launch of a AmnioStem universal donor stem cell programme in treating cancer associated wasting (Cachexia) under President Trump's new Right to Try law.
The company aims at treating cancer associated wasting through the in-licensing of patent application #15/814284 entitled "Treatment of Cachexia Using Stem Cells and Products Thereof".
According to the company, the data from the AmnioStem stem cell was superior to other stem cell types at reducing inflammatory mediators, including TNF-alpha. The inflammatory mediators generated by cancer have a pivotal contribution to cancer associated weight loss, formally termed "cachexia".
Through the suppression of inflammatory mediators, as well as direct anticancer effect of amniotic fluid stem cells, the company expects the AmnioStem may provide value in the treatment of advanced cancer patients.
Cachexia is a very severe complication of cancer: weight loss during treatment is associated with more side effects of chemotherapy, fewer cycles of chemotherapy, a lower response to therapy and decreased survival. About 20% of cancer patients die due to cachexia and 50% of patients die with cachexia.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007